Details

Autor(en) / Beteiligte

• Lv, Wen-He
• Dong, Jian-Zeng
• Du, Xin
• Hu, Rong
• He, Liu
• Long, De-Yong
• Sang, Cai-Hua
• Jia, Chang-Qi
• Feng, Li
• Li, Xu
• Ning, Man
• Chen, Xuan
• Cui, Yi-Kai
• Tang, Ri-Bo
• Ma, Chang-Sheng

Titel

Antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation and chronic coronary syndrome

Ist Teil von

• Journal of thrombosis and thrombolysis, 2022-05, Vol.53 (4), p.868-877

Ort / Verlag

New York: Springer US

Erscheinungsjahr

2022

Quelle

MEDLINE

Beschreibungen/Notizen

• This study aimed to explore antithrombotic strategy and its relationship with outcomes in patients with atrial fibrillation (AF) at high risk for stroke and chronic coronary syndrome (CCS) in real-world clinical practice. Patients with AF at high risk for stroke complicated with CCS from China Atrial Fibrillation Registry (CAFR) were enrolled. The patients were divided into non-antithrombotic (Non-AT) group, oral anticoagulants (OAC) group, antiplatelet therapy (APT) group (aspirin or clopidogrel), and dual antiplatelet therapy (DAPT) group (aspirin + clopidogrel) according to their antithrombotic strategies at baseline. The patients with OAC + single antiplatelet drug (14 cases) and OAC + dual antiplatelet therapy (7 cases) were excluded for the small sample size. The primary effectiveness outcome was the composite outcome of coronary events, thromboembolism, and all-cause mortality. The primary safety outcome was major bleeding events. From 2011 to 2018, 25,512 patients were included in the CARF study, 769 patients with AF at high risk for stroke and CCS were enrolled in this study. After a follow-up of 47.4 ± 25.3 months, the incidences of primary effectiveness outcome were 44.6%, 25.7%, 43.6%, and 29.1% in the four groups, respectively ( P  < 0.001). The incidences of primary effectiveness and all-cause mortality were both significantly lower in the OAC group than in the Non-AT group, (25.7% vs. 44.6%, HR 0.53, 95% CI 0.39–0.73, P  < 0.001) and (14.6% vs. 38.5%, HR 0.36, 95%CI 0.25–0.52, P  < 0.001). In multivariate analysis, age (HR 1.03, 95%CI 1.01–1.05, P  = 0.015), heart failure (HR 1.67, 95%CI 1.20–2.33, P  = 0.002) and OAC (HR 0.66, 95%CI 0.47–0.91, P  = 0.012) were independent factors for the composite outcome. There was no significant difference in major bleeding events between the four groups. OAC monotherapy significantly reduced the primary effectiveness composite outcome and all-cause mortality in the patients with AF at high risk for stroke complicated with CCS. However, there was no significant difference in major bleeding among the different antithrombotic strategies. Trial Registration www.chictr.org.cn (No. ChiCTR-OCH-13003729).